| Not Yet Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With La Late-onset Pompe Disease | Phase 1 | 2026-03-01 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants Alzheimer Disease, Early Onset | Phase 1 | 2026-01-30 |
| Recruiting | Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2 Parkinson Disease | Phase 2 | 2024-10-24 |
| Completed | A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Or Healthy Volunteers | Phase 1 | 2024-03-01 |
| Active Not Recruiting | Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A) Mucopolysaccharidosis Type IIIA | Phase 1 / Phase 2 | 2023-12-07 |
| Enrolling By Invitation | An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Partic Mucopolysaccharidosis II | Phase 2 / Phase 3 | 2023-09-20 |
| Recruiting | A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and You Mucopolysaccharidosis II | Phase 2 / Phase 3 | 2022-07-21 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Part Healthy Participant | Phase 1 | 2022-07-14 |
| Active Not Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Part Frontotemporal Dementia | Phase 1 / Phase 2 | 2022-02-01 |
| Completed | A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotro Amyotrophic Lateral Sclerosis | Phase 1 | 2021-08-11 |
| Completed | A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2020-12-23 |
| Active Not Recruiting | A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome Mucopolysaccharidosis II | Phase 1 / Phase 2 | 2020-07-16 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volu Healthy Volunteers | Phase 1 | 2020-02-20 |
| Completed | A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome Mucopolysaccharidosis II | — | 2019-10-23 |
| Completed | Study to Evaluate DNL747 in Subjects With Alzheimer's Disease Alzheimer Disease | Phase 1 | 2019-02-13 |
| Completed | Study to Evaluate DNL201 in Subjects With Parkinson's Disease Parkinson Disease | Phase 1 | 2018-12-04 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volu Healthy Volunteers | Phase 1 | 2017-11-16 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volu Healthy Volunteers | Phase 1 | 2017-06-01 |